Outpatient calcium-channel blockers and the risk of postpartum haemorrhage: a cohort study.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 24020971.
- Also identified by DOI 10.1111/1471-0528.12428 and PMC identifier 3866215.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To determine whether outpatient exposure to calcium-channel blockers (CCBs) at the time of delivery is associated with an increased risk for postpartum haemorrhage (PPH). Cohort study. United States of America. Medicaid beneficiaries. We identified a cohort of 9750 patients with outpatient prescriptions for CCBs, methyldopa, or labetalol for pre-existing or gestational hypertension whose days of supply overlapped with delivery; 1226 were exposed to CCBs. The risk of PPH was compared in those exposed to CCBs to those exposed to methyldopa or labetalol. Propensity score matching and stratification were used to address potential confounding. The occurrence of PPH during the delivery hospitalisation. There were 27 patients exposed to CCBs (2.2%) and 232 patients exposed to methyldopa or labetalol (2.7%) who experienced PPH. After accounting for confounders, there was no meaningful association between CCB exposure and PPH in the propensity score matched (odds ratio 0.77, 95% CI 0.50-1.18) or stratified (odds ratio 0.79, 95% CI 0.53-1.19) analyses. Similar results were obtained across multiple sensitivity analyses. The outpatient use of CCBs in late pregnancy for the treatment of hypertension does not increase the risk of PPH.
Medical subject headings
- Calcium Channel Blockers
- Hypertension
- Postpartum Hemorrhage